<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Tarek</forename><surname>Bekfani</surname></persName>
							<email>tarek.bekfani@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Internal Medicine I</orgName>
								<orgName type="department" key="dep2">Division of Cardiology, Angiology, Pneumology and Intensive Medical Care</orgName>
								<orgName type="institution">Friedrich-Schiller-University</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pierpaolo</forename><surname>Pellicori</surname></persName>
							<email>pierpaolo.pellicori@hey.nhs.uk</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">University of Hull</orgName>
								<address>
									<settlement>Hull</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University of Göttingen Medical School</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Daniel</forename><forename type="middle">A</forename><surname>Morris</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicole</forename><surname>Ebner Msc</surname></persName>
							<email>nicole.ebner@med.uni-goettingen.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD §, ¶</roleName><forename type="first">Miroslava</forename><surname>Valentova</surname></persName>
							<email>miroslava.valentova@med.uni-goettingen.de</email>
							<affiliation key="aff4">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Comenius University</orgName>
								<address>
									<settlement>Bratislava</settlement>
									<country key="SK">Slovak Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lisa</forename><surname>Steinbeck</surname></persName>
							<email>lisa.steinbeck@gmx.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Rolf</forename><surname>Wachter</surname></persName>
							<email>wachter@med.uni-goettingen.de</email>
						</author>
						<author>
							<persName><forename type="first">Sebastian</forename><surname>Elsner</surname></persName>
							<email>sebastian.elsner@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Veronika</forename><surname>Sliziuk</surname></persName>
							<email>veronika.sliziuk@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD $</roleName><forename type="first">Joerg</forename><forename type="middle">C</forename><surname>Schefold</surname></persName>
							<email>joerg.schefold@insel.ch</email>
							<affiliation key="aff5">
								<orgName type="department">Deptartment of Intensive Care Medicine</orgName>
								<orgName type="institution">University Hospital of Bern</orgName>
								<address>
									<settlement>Inselspital, Bern</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD §</roleName><forename type="first">Anja</forename><surname>Sandek</surname></persName>
							<email>anja.sandek@med.uni-goettingen.de</email>
						</author>
						<author>
							<persName><roleName>MD PhD FESC</roleName><forename type="first">Wolfram</forename><surname>Doehner</surname></persName>
							<email>wolfram.doehner@charite.dej.g.cleland@hull.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charité Medical School</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD †</roleName><forename type="first">John</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">University of Hull</orgName>
								<address>
									<settlement>Hull</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University of Göttingen Medical School</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mitja</forename><surname>Lainscak</surname></persName>
							<email>mitja.lainscak@guest.arnes.si</email>
							<affiliation key="aff7">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Golnik University</orgName>
								<address>
									<settlement>Golnik</settlement>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD PhD FESC §</roleName><forename type="first">Stefan</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
							<email>s.anker@cachexia.de</email>
						</author>
						<author>
							<persName><roleName>MD PhD FESC</roleName><forename type="first">Stephan</forename><surname>Von Haehling</surname></persName>
							<email>stephan.von.haehling@web.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Charité Medical School</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Institute of Innovative Clinical Trials Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University of Göttingen Medical School Robert-Koch-Strasse 40</orgName>
								<address>
									<postCode>D -37075</postCode>
									<settlement>Göttingen, Göttingen</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">634592E7A34E27A41D21D762F27D2122</idno>
					<idno type="DOI">10.1016/j.ijcard.2016.07.135)</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:10+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Heart failure with preserved ejection fraction -muscle wastingsarcopenia -exercise capacity -quality of life</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: To describe the prevalence of sarcopenia in ambulatory patients with heart failure with preserved ejection fraction (HFpEF) and its relation to reduced exercise capacity, muscle strength, and quality of life (QoL).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods and Results:</head><p><s>A total of 117 symptomatic outpatients with HFpEF were prospectively enrolled in Germany, England, and Slovenia as part of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).</s><s>Appendicular skeletal muscle (ASM) mass (the sum of muscle mass in both arms and legs) was assessed by DEXA.</s></p><p><s>Echocardiography, 6-minute walk testing (6-MWT), muscle strength assessment, spiroergometry and QoL evaluation using EQ-5D Questionnaire were performed.</s><s>Sarcopenia was defined as ASM 2 standard deviations below the mean of a healthy reference group aged 18-40 years.</s><s>Patients were divided into 3 groups according to the E/e' value: ≤8, 9-14, and ≥15.</s><s>Sarcopenia was detected in 19.7% of all patients.</s><s>These patients performed worse during 6-MWT (404±116 vs. 307±145 meters, p=0.003) and showed lower absolute peak oxygen consumption (1579±474 vs. 1211±442 ml/min, P&lt;0.05).</s><s>Both ASM and muscle strength were lowest in patients with E/e'&gt;15 (P&lt;0.05).</s><s>Higher values of muscle strength/ASM were associated with a better QoL (r=0.5, p&lt;0.0005).</s><s>Logistic regression showed ASM to be independently associated with reduced distance walked during the 6-MWT adjusted for NYHA, height, left atrium diameter, ferritin and forced expiratory volume in 1 second (FEV1) (odds ratio 1.2, p=0.02).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p><s>Sarcopenia affects a clinically relevant proportion of patients with HFpEF.</s><s>Low ASM is strongly linked to reduced muscle strength, exercise capacity and QoL in these patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>Heart failure (HF) is a major public health problem.</s><s>About 50% of all patients with HF present with preserved left ventricular ejection fraction (HFpEF) on imaging tests <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b1">2)</ref>.</s></p><p><s>The main symptom of these patients with HFpEF is dyspnea or early fatigue <ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref>.</s><s>The underlying causes are heterogeneous and not well understood.</s><s>Several mechanisms might have a role in explaining the pathophysiology, as for example reduced left ventricular (LV) longitudinal strain function <ref type="bibr" target="#b5">(6)</ref>, and higher LV filling pressures <ref type="bibr" target="#b6">(7)</ref>.</s><s>Recent studies suggest that peripheral factors such as skeletal muscle abnormalities may contribute to decreased maximal oxygen consumption (peak VO2) and may explain its improvement after exercise training <ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref>.</s></p><p><s>After the age of 50, muscle mass declines by 1-2% annually <ref type="bibr" target="#b12">(13)</ref> and muscle strength by about 1.5%; this process accelerates to as much as 3% per year after age 60 <ref type="bibr" target="#b13">(14)</ref>.</s><s>Such agerelated loss of skeletal muscle mass and function is part of the normal aging process and has been termed sarcopenia or muscle wasting <ref type="bibr" target="#b14">(15)</ref>, and it affects about 10% of elderly healthy subjects aged 60-70 years <ref type="bibr" target="#b11">(12,</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref>.</s><s>The 2016 HF guidelines of the European Society of Cardiology acknowledge sarcopenia as an important co-morbidty of HF that requires particular attention <ref type="bibr" target="#b17">(18)</ref>, because wasting processes are accelerated and more pronounced in chronic diseases including HF <ref type="bibr" target="#b18">(19)</ref>.</s><s>The prevalence of sarcopenia in a mixed cohort of patients with symptomatic chronic HF was found to be 19.5% in a recently published study by our group <ref type="bibr" target="#b9">(10)</ref>.</s><s>However, its prevalence in a highly selected HFpEF cohort and its association with exercise capacity and muscle strength in these patients have not been investigated yet.</s></p><p><s>The Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) were designed as an observational study into the co-morbidities of HF, whether with reduced or preserved ejection fraction <ref type="bibr" target="#b19">(20)</ref>.</s><s>The project was jointly funded by the European Commission and the Russian Ministry of Health.</s><s>Using data from SICA-HF, the present study aimed to investigate the prevalence and clinical effects of sarcopenia in patients with HFpEF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Study population</head><p><s>We included symptomatic out-patients with HFpEF enrolled between March 2010 and September 2013 into SICA-HF, a European observational multi-center study investigating the prevalence, incidence and impact of key co-morbidities of HF in out-patients with a clinical diagnosis of chronic HF.</s><s>For this sub-study, subjects were recruited from the Departments of Cardiology at the Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany (n=61, 52.1%); Hull University Hospital, Hull, England (n=32, 27.4%); and Golnik University Hospital, Golnik, Slovenia (n=24, 20.5%).</s><s>All subjects provided written informed consent at enrolment, and the protocol was approved by the responsible ethical review boards <ref type="bibr" target="#b19">(20)</ref>.</s><s>The study was funded by the European Commission's 7 th Framework program (FP7/2007-2013) under grant agreement number 241558 and fulfilled all principles of the Declaration of Helsinki.</s><s>The protocol is registered at clinicaltrials.gov</s><s>under the unique identifier number NCT01872299.</s></p><p><s>HFpEF was defined as the presence of signs and symptoms of HF combined with an LVEF ≥50% on echocardiography and dilated left atrium (left atrial volume index ≥34 ml/m 2 as assessed using the Du Bois formula for estimating the body surface area) and/or evidence of diastolic dysfunction on tissue doppler examination (septal e' &lt;8, and/or lateral e' &lt;10) <ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref>.</s><s>Patients with severe valve abnormalities were excluded in the present analysis.</s><s>Overall, 117 patients fulfilled these criteria.</s><s>Patients were further sub-grouped into one of three groups according to E/e' value with e' being the average of septal and lateral values in this equation as ≤8 (group A), 9-14 (group B), ≥15 (group C ) <ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Assessment of muscle strength, muscle function, and functional capacity</head><p><s>Body composition analysis was performed using dual energy X-ray absorptiometry (DEXA) with a Lunar Prodigy device together with Lunar en Core 2002 software (both from GE Medical Systems, Madison, WI, USA).</s><s>Appendicular skeletal muscle mass (ASM) that includes non-fat and non-bone tissue in both arms and legs combined in grams was analyzed in all patients to evaluate skeletal muscle mass according to the definition of sarcopenia (muscle wasting) <ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref>.</s><s>In accordance with previously published consensus statements and using reference values (7.26 kg in men vs. 5.45 kg in women) from the previously published younger (age range: 18-40 years) Rossetta cohort <ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref>, sarcopenia was defined as muscle mass 2 standard deviations below the mean of the reference values in this reference population.</s><s>The ratio resulting from indexing appendicular lean mass to body height (in meters squared) was used to separate patients with and without sarcopenia <ref type="bibr" target="#b26">(27)</ref>.</s></p><p><s>Muscle strength was assessed in 54 patients as handgrip strength (HGS) using a handgrip dynamometer (Saehan Coporation Korea Hydraulic Hand Dynamometer, model SH5001).</s><s>Knee extension (quadriceps) strength was measured in 54 patients using isokinetic dynamometer (Multitrace 2, Lectromed, Jersey, Channel Islands) in both legs in a sitting position with the patient's legs hanging freely, the ankle fixed by a pressure transducer (kilograms).</s><s>The best of three measurements was used in each of the hand-and knee extension strength tests as defined in the protocol <ref type="bibr" target="#b19">(20)</ref>.</s><s>The maximum uptake of oxygen (peak VO2 in mL/kg/min or absolute peak VO2 in mL/min) was measured using spiroergometry with a treadmill and the modified Bruce protocol (50 patients) <ref type="bibr" target="#b27">(28)</ref>.</s><s>In selected patients, the modified Naughton protocol was used <ref type="bibr" target="#b28">(29)</ref>.</s><s>In addition, a 6-minute corridor walk test (6-MWT) was performed in 86 patients.</s><s>As part of the co-morbidities work-up, patients were also screened for the presence of iron deficiency, defined as ferritin &lt; 100 µg /L or 100-299 µg/L and transferrin saturation (TSAT) &lt; 20% 2.3.</s><s>Quality of life assessment Quality of life was assessed using the VAS (Visual Analogue Scale), which is part of the European Quality of Life-5 Dimensions (EQ-5D) questionnaire <ref type="bibr" target="#b29">(30)</ref>.</s><s>This questionnaire captures a self-rating of health status on a 20-cm vertical VAS, anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) at the bottom the score.</s><s>EQ-5D (VAS) ratings are a quantitative measure, and differences in this scale can be used as a measure of outcome, as judged by the individual respondents (31-32).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Statistical analysis:</head><p><s>Data are presented as mean ± standard deviation (SD) or median with percentiles.</s><s>StatView</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head><p><s>We enrolled a total of 117 patients with HFpEF who were symptomatic with a mean New York Heart Association (NYHA) class NYHA 2.4±0.5 with most patients (60.2%) being in NYHA class II (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Of all patients, 38 (32.5%) were female, and 22 were found to have E/e' values ≤8, 79 had moderately elevated E/e' between 9 and 14, and 16 had elevated values E/e' ≥15.</s><s>Twenty-three of all patients with HFpEF (19.7%) were found to fulfill the criteria of sarcopenia, 87% of them were males.</s><s>Patients with sarcopenia performed worse on the 6-MWT (404±116 vs. 307±145 meters, p=0.003), showed lower absolute peak VO2 (1579±474 vs. 1211±442 mL/min, p&lt;0.05) and had shorter exercise time (604±177 vs. 477±152 seconds, p=0.03), lower VE/VCO2 (31±6 vs. 37±4, p= 0.01) on spiroergometry testing (see Table <ref type="table" target="#tab_0">1</ref>, Figures <ref type="figure" target="#fig_2">1a-1b</ref>).</s></p><p><s>By dividing the HFpEF cohort into subgroups according to E/e' we found that there was a steady reduction of appendicular lean mass (ASM/BMI) with increased severity of diastolic dysfunction (group A 0.84±0.19 vs. group B 0.76±0.16</s><s>vs. group C: 0.71±0.11,</s><s>p = 0.03) (Table <ref type="table" target="#tab_1">2</ref>).</s><s>The same applied for handgrip strength in both hands (Figure <ref type="figure" target="#fig_3">2a</ref>), and knee extension strength measurements (Figure <ref type="figure" target="#fig_4">2b</ref>).</s><s>A trend was noted with regards to exercise time on spiroergometry testing with patients with more severe diastolic dysfunction having shorter exercise duration values (group A 705±170 vs. group B 552±169, vs. group C 576±201 seconds, p=0.06).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Correlation analyses</head><p><s>Lower values for appendicular lean mass were associated with more severe diastolic dysfunction as measured by E/e' (r=-0.22,</s><s>p&lt;0.02; Figure <ref type="figure" target="#fig_5">3</ref>).</s><s>Using simple regression, we found higher values of ASM to be positively associated with a higher value of absolute peak VO2 (r=+0.67,</s><s>p&lt;0.0001, Figure <ref type="figure" target="#fig_6">4</ref>), muscle strength in hands and legs in both sides ([right hand: r=+0.59,</s><s>p&lt;0.0001; left hand: r=+0.62,</s><s>p&lt;0.0001], [right leg: r=+0.37,</s><s>p&lt;0.006; left leg: r=+0.47,</s><s>p=0.0003]), exercise time (r=+0.33,</s><s>p=0.01), and 6-MWT (r=+0.30,</s><s>p=0.003).</s><s>Furthermore, higher peak VO2 was seen in patients with higher values of muscle strength in arms (p&lt;0.001) and legs (p&lt;0.01).</s><s>Higher muscle strength/muscle mass (both in kg) was associated with higher quality of life in HFpEF patients estimated by the VAS-Score ([left leg: r=+0.5, p= 0.001], right leg: [r=+0.</s><s><ref type="bibr">38, p=0</ref>.01],</s><s>Figures <ref type="figure" target="#fig_7">5a and 5b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Exercise Capacity</head><p><s>A 6-MWT distance was covered by 86 (73.5%) of all patients, 19 (22.1%) of those with sarcopenia and 67 (77.9%) of those without (p=0,003).</s><s>Univariate logistic regression showed that FEV1, FVC, NYHA class, height, ferritin, left atrium diameter, quadriceps strength and ASM were all associated with reduced exercise capacity evaluated by 6-MWT, defined as a distance walked &lt;400 m during the test (all p&lt;0.05).</s><s>This was not the case for age, sex, E/e', LVEF, anemia, Hb, or the presence of iron deficiency.</s><s>Multivariable logistic regression showed that appendicular lean mass remained independently associated with reduced exercise capacity after adjustment for parameters found to be statistically significant predictors on univarite analysis (odds ratio 1.2-per 500g increase of appendicular lean mass, 95% confidence interval 1.03-1.33,</s><s>p=0.02) (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>The main symptom in patients with HFpEF is exercise intolerance whose etiology has been deemed multifactorial.</s><s>The role of peripheral factors, such as skeletal muscle mass, strength and function, is poorly understood.</s><s>This is the first multicenter European study that describes the prevalence of sarcopenia in patients with HFpEF and its impact on exercise capacity, muscle strength, and quality of life.</s><s>Overall, 19.7% of the symptomatic stable HFpEF out-patients in our cohort presented with sarcopenia, i.e. muscle wasting.</s><s>These patients showed reduced exercise capacity, measured objectively in the cardiopulmonary exercise test as well as in 6-MWT.</s><s>Furthermore, scores of the VAS (Visual Analogue Scale) derived from the EQ-5D showed higher quality of life in patients with higher values of the ratio muscle strength/muscle mass.</s><s>In addition, there was a steady increase in absolute peak VO2 in parallel to the increased values of ASM.</s><s>This could support the supposed role of muscle mass in explaining reduced exercise tolerance in patients with HFpEF and its improvement after exercise training <ref type="bibr" target="#b10">(11)</ref>.</s></p><p><s>In our previously published study of a mixed cohort of patients with HF, we described the prevalence of sarcopenia (muscle wasting) in patients with chronic HF with either HF with reduced LVEF or HF with dilated atrium (diameter &gt;40 mm) and LVEF &gt;40% <ref type="bibr" target="#b19">(20)</ref>.</s><s>The prevalence of muscle wasting in the overall cohort was 19.5%, with lower values in the group with only mildly reduced or normal LVEF.</s><s>However, using a more restrictive definition of HFpEF in the present study, we found the prevalence of sarcopenia in patients with HFpEF as defined by the European and American Societies of Cardiology and Echocardiography to be very similar to that of the mixed cohort <ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref>.</s><s>Patients in the present cohort had typical characteristics of HFpEF.</s><s>Most of the patients with severe diastolic dysfunction (E/e'≥15) were women, had higher cardiac muscle mass index, left atrium volume index (LAVI), and estimated systolic pulmonary artery pressure.</s><s>The prevalence of sarcopenia among patients with enlarged atrium and LVEF &gt;40% in the mixed cohort was lower than that of patients with reduced ejection fraction.</s><s>We believe that the difference in the prevalence of sarcopenia between the two studies is due to the different definitions and more sophisticated characteristics of HFpEF in the present study.</s></p><p><s>It is known that muscle undergoes changes such as decline in muscle mass and muscle strength as part of the pathophysiology of the ageing process <ref type="bibr" target="#b11">(12)</ref>.</s><s>These changes include a switch in the muscle fibers types from fast type II to the slow type I fibers and a reduction in capillary density <ref type="bibr" target="#b32">(33,</ref><ref type="bibr" target="#b33">34)</ref>.</s><s>This may result in reduced physical performance.</s><s>The prevalence of muscle wasting described in healthy adults aged 60-70 years is 5-13% <ref type="bibr" target="#b11">(12)</ref>.</s><s>Our finding of almost 20% of HFpEF patients to have sarcopenia is considerably higher than what was expected according to the age category alone.</s><s>Sarcopenia can be observed in many other chronic diseases like chronic obstructive pulmonary disease (COPD).</s><s>One study found that 14.5% of patients of COPD had sarcopenia, and prevalence was higher with worsening of COPD status <ref type="bibr" target="#b34">(35)</ref>.</s><s>The pathophysiology of muscle wasting in patients with chronic diseases is not entirely clear yet.</s><s>Signaling pathways may be different in healthy aging and in patients with chronic diseases with higher inflammatory load and thus more pronounced proteasome activity in patients with chronic disease, thus serving as a basis for active myofibril degeneration <ref type="bibr" target="#b33">(34,</ref><ref type="bibr" target="#b38">39)</ref>.</s><s>Indeed, one of the hypotheses holds that inflammatory processes, which accompany many chronic diseases, may lead to metabolic changes.</s><s>These, in turn, lead to an imbalance between anabolic and catabolic signals <ref type="bibr" target="#b35">(36)</ref>.</s><s>The stimulation of catabolic pathways induces protein breakdown and as a result affects skeletal muscle <ref type="bibr" target="#b36">(37)</ref>.</s><s>Pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-(TNF-α) intensify catabolism <ref type="bibr" target="#b37">(38,</ref><ref type="bibr" target="#b38">39)</ref>.</s><s>We detected significantly elevated serum levels of IL-6 among HF patients with muscle wasting already in our previously published study in patients with chronic HF <ref type="bibr" target="#b9">(10)</ref>.</s></p><p><s>Our results could open a new horizon in the treatment targets of patients with HFpEF through developing new nutritional or hormonal treatments <ref type="bibr" target="#b39">(40)</ref> or by developing special exercise training programs as recommended from the European Society of Cardiology in patients with HF <ref type="bibr" target="#b40">(41)</ref>.</s><s>This may lead to improve muscle mass, muscle strength, exercise capacity <ref type="bibr" target="#b10">(11,</ref><ref type="bibr" target="#b41">42)</ref>, and as a result the quality of life in this group of patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions:</head><p><s>This multi-center study shows that patients with HFpEF are at least as frequently affected by sarcopernia as patients in mixed cohort described previously that predominantly embraced patients with reduced ejection fraction.</s><s>Patients with HFpEF and sarcopenia have worse exercise capacity as assessed in the cardiopulmonary test and in the 6-MWT as well as worse QoL.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.">Conflict of interest:</head><p><s>SvH is consulting and has received honoraria for speaking from Solartium Dietetics, Professional Dietetics, Vifor, Novartis, Chugai, Respicardia, Sorin, and Pfizer.</s><s>SDA is consulting, has received honoraria for speaking and/or attended advisory boards for Amgen Inc, Professional Dietetics, Psioxus Therapeutics, GTx, Helsinn, GSK, Sanofi, Regeneron, Novartis, Takeda, Servier, Chugai and Vifor.</s><s>All other authors report no conflict of interest.</s><s>9. Tables:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.">Figure legends:</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>5. 0 (</head><label>0</label><figDesc><div><p><s>SAS Institute, inc., Cary, USA) and the Statistical Package for the Social Sciences (version 21, IBM Cop.</s><s>Armonk, NY, USA) were used for statistical analysis.</s><s>Analysis of variance (ANOVA), Student's unpaired t-test, Fisher's exact test, Pearson's simple and logistic regression were used as appropriate.</s><s>A two-tailed p-value ≤0.05 indicates statistical significance.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1a :</head><label>1a</label><figDesc><div><p><s>Figure 1a: Exercise capacity assessed by the distance walked in 6-min walk test in patients</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 1b :</head><label>1b</label><figDesc><div><p><s>Figure 1b: Absolute peak VO2 assessed by a treadmill in the spiroergometry test in patients</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2a :</head><label>2a</label><figDesc><div><p><s>Figure 2a: Handgrip strength as assessed by a handgrip dynamometer in patients of different</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 2b :</head><label>2b</label><figDesc><div><p><s>Figure 2b: Quadriceps strength assessed by an isokinetic dynamometer in patients of different</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Simple regression analysis of appendicular lean mass and E/e'.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: Simple regression analysis of appendicular lean mass and absolute peak VO2.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 5a -</head><label>5a</label><figDesc><div><p><s>Figure 5a-5b: Simple regression analysis of Muscle strength/muscle mass (both in kg) of both legs and quality of life assessed by VAS-Score.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head></head><label></label><figDesc><div><p><s>Figure 1a</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 :</head><label>1</label><figDesc><div><p><s>Baseline characteristics of patients with muscle wasting vs. without muscle wasting:</s></p></div></figDesc><table><row><cell>Variable</cell><cell>All Patients</cell><cell>Patients without</cell><cell>Patients with</cell><cell>P-Value</cell></row><row><cell></cell><cell>(n=117)</cell><cell>muscle wasting</cell><cell>muscle</cell><cell></cell></row><row><cell></cell><cell></cell><cell>(n=94)</cell><cell>wasting</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(n=23)</cell><cell></cell></row><row><cell>Sex (m/f %)</cell><cell>67.5/32.5</cell><cell>62.8/37.2</cell><cell>87/13.0</cell><cell>0.03</cell></row><row><cell>Age (years)</cell><cell>69.8±8.5</cell><cell>69.1±8.4</cell><cell>72.3±8.5</cell><cell>0.11</cell></row><row><cell>Weight (kg)</cell><cell>89.27±19.53</cell><cell>92.75±18.40</cell><cell>75.05±17.78</cell><cell>&lt; 0.0001</cell></row><row><cell>BMI (kg/m²)*</cell><cell>30.95±6.57</cell><cell>32.18±6.36</cell><cell>25.69±4.68</cell><cell>&lt; 0.0001</cell></row><row><cell>Hip circumference (cm)</cell><cell cols="2">112.11±12.69 113.42±12.87</cell><cell>105.29±9.33</cell><cell>0.02</cell></row><row><cell>NYHA</cell><cell>2.4±0.5</cell><cell>2.3±0.5</cell><cell>2.7±0.5</cell><cell>0.002</cell></row><row><cell>Hypertension (present)</cell><cell>89%</cell><cell>89%</cell><cell>90%</cell><cell>&gt;0.99</cell></row><row><cell cols="2">Diabetes mellitus (present) 48%</cell><cell>50%</cell><cell>33%</cell><cell>0.48</cell></row><row><cell cols="2">Atrial fibrillation (present) 25%</cell><cell>28%</cell><cell>10%</cell><cell>0.15</cell></row><row><cell>Hemoglobin (g/dL)</cell><cell>13.5±1.6</cell><cell>13.4±1.6</cell><cell>13.8±1.7</cell><cell>0.33</cell></row><row><cell>Creatinin (mg/dL)</cell><cell>1.1±0.4</cell><cell>1.1±0.4</cell><cell>1.1±0.5</cell><cell>0.82</cell></row><row><cell cols="2">LDL-Cholesterol (mg/dL) 102.3±42.5</cell><cell>102.1±44.0</cell><cell>100.1±36.8</cell><cell>0.85</cell></row><row><cell>Ferritin (ng/mL)</cell><cell>186.9±194.9</cell><cell>197.6±201.3</cell><cell>142.1±162.1</cell><cell>0.24</cell></row><row><cell>LVEF % ‡</cell><cell>58.8±7.3</cell><cell>58.5±6.8</cell><cell>59.9±9.3</cell><cell>0.42</cell></row><row><cell>Left ventricular mass</cell><cell cols="2">126.94±36.26 127.94±38.30</cell><cell>122.73±26.35</cell><cell>0.55</cell></row><row><cell>index (gm/m 2 )</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>LAVI (ml/m 2 ) §</cell><cell>37.44±13.57</cell><cell>38.07±13.94</cell><cell>32.71±9.61</cell><cell>0.24</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 :</head><label>2</label><figDesc><div><p><s>Baseline characteristics of HFpEF patients *LAVI: Left atrium volume index, †PAP: Pulmonary artery pressure, §LVEDVI: Left ventricular end diastolic volume index, ¶LVESVI: Left ventricular end systolic volume index.</s><s>‡LVEF: Left ventricular ejection fraction.</s></p></div></figDesc><table><row><cell>PAP (mmm/Hg) †</cell><cell>35.61±10.24</cell><cell cols="2">35.06±10.17</cell><cell>38.14±10.89</cell><cell>0.45</cell></row><row><cell>Variable</cell><cell cols="2">Group A</cell><cell>Group B</cell><cell>Group C</cell><cell>p Value</cell></row><row><cell></cell><cell>E/e' ≤8</cell><cell></cell><cell>E/e' 9-14</cell><cell>E/e' ≥15</cell><cell>ANOVA</cell></row><row><cell></cell><cell>n=22</cell><cell></cell><cell>n=79</cell><cell>n=16</cell></row><row><cell>Age (years)</cell><cell cols="2">67.9±8.5</cell><cell>70.2±8.4</cell><cell>70.0±9.1</cell><cell>0.53</cell></row><row><cell>Sex (m/f %)</cell><cell cols="2">77.3/22.7</cell><cell>70.9/29.1</cell><cell>37.5/62.5</cell><cell>0.02</cell></row><row><cell>BMI (kg/m 2 )</cell><cell cols="2">29.88±6.75</cell><cell>31.02±6.82</cell><cell>31.21±5.14</cell><cell>0.70</cell></row><row><cell>NYHA</cell><cell cols="2">2.22±0.43</cell><cell>2.46±0.50</cell><cell>2.31±0.48</cell><cell>0.14</cell></row><row><cell>Left ventricular mass index</cell><cell cols="4">111.30±28.54 127.33±35.55 145.57±41.21</cell><cell>0.02</cell></row><row><cell>(gm/m 2 )</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>LAVI(ml/m 2 )*</cell><cell cols="2">35.00±18.36</cell><cell>36.21±9.48</cell><cell>45.43±16.34</cell><cell>&lt; 0.05</cell></row><row><cell>E/A</cell><cell cols="2">0.98±0.52</cell><cell>0.99±0.59</cell><cell>1.5±0.98</cell><cell>0.04</cell></row><row><cell>PAP (mmHG) †</cell><cell cols="2">34.27±7.85</cell><cell>34.08±10.45</cell><cell>47.43±5.23</cell><cell>0.02</cell></row><row><cell>LVEDVI (ml/m 2 ) §</cell><cell cols="2">52.69±16.51</cell><cell>51.27±15.37</cell><cell>52.76±16.79</cell><cell>0.92</cell></row><row><cell>LVESVI (ml/m 2 ) ¶</cell><cell cols="2">23.23±9.16</cell><cell>22.33±8.20</cell><cell>21.23±8.95</cell><cell>0.79</cell></row><row><cell>LVEF (%) ‡</cell><cell cols="2">57.68±5.81</cell><cell>58.81±7.62</cell><cell>60.00±7.77</cell><cell>0.63</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 :</head><label>3</label><figDesc><div><p><s>Logistic regression model with reduced exercise capacity (defined as 6-MWT below 400 m) serving as the dependent variable.</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Univariate</cell><cell></cell><cell>Multivariate</cell><cell></cell><cell></cell></row><row><cell></cell><cell>OR</cell><cell>95% CI</cell><cell>P-Value</cell><cell>OR</cell><cell>95% CI</cell><cell>P-Value</cell></row><row><cell>Age (per year increase)</cell><cell>1.01</cell><cell>0.96-1.06</cell><cell>0.72</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Sex (female)</cell><cell>0.60</cell><cell>0.24-1.51</cell><cell>0.27</cell><cell></cell><cell></cell><cell></cell></row><row><cell>NYHA (per 1 class increase)</cell><cell>9.37</cell><cell cols="2">3.22-27.20 &lt;0.0001</cell><cell>13.29</cell><cell>2.73-64.62</cell><cell>0.001</cell></row><row><cell>Height (per 10 cm increase)</cell><cell>0.49</cell><cell>0.29-0.84</cell><cell>0.009</cell><cell>0.52</cell><cell>0.16-1.72</cell><cell>0.28</cell></row><row><cell>BMI (per kg/m² increase)</cell><cell>1.02</cell><cell>0.95-1.09</cell><cell>0.63</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Atrial fibrillation (present)</cell><cell>1.25</cell><cell>0.64-5.44</cell><cell>0.86</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Left atrium diameter (per 1</cell><cell>0.27</cell><cell>0.12-0.64</cell><cell>0.003</cell><cell>0.4</cell><cell>0.09-1.78</cell><cell>0.23</cell></row><row><cell>mm increase)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>E/e' (per 1 unit increase)</cell><cell>0.99</cell><cell>0.91-1.09</cell><cell>0.88</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Peak VO2 (per 1 ml/kg/min</cell><cell>0.37</cell><cell>0.19-0.72</cell><cell>0.003</cell><cell></cell><cell></cell><cell></cell></row><row><cell>increase)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>FEV1 (per 1 L/s increase)</cell><cell>0.21</cell><cell>0.1-0.46</cell><cell>&lt;0.0001</cell><cell>0.1</cell><cell>0.02-0.26</cell><cell>0.006</cell></row><row><cell>FVC (per 1 L increase)</cell><cell>0.44</cell><cell>0.24-0.79</cell><cell>0.006</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Anemia (present)</cell><cell>0.98</cell><cell>0.37-2.61</cell><cell>0.97</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Iron deficiency (present)</cell><cell>0.57</cell><cell>0.23-1.38</cell><cell>0.21</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ferritin (per 1ng/mL</cell><cell>1.0</cell><cell>0.99-1.00</cell><cell>0.02</cell><cell>1.0</cell><cell>0.99-1.00</cell><cell>0.5</cell></row><row><cell>increase)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 :</head><label>4</label><figDesc><div><p><s>Patients' medication at study entry</s></p></div></figDesc><table><row><cell></cell><cell>All patients %</cell><cell>Patients with</cell><cell>Patients without</cell><cell>P-</cell></row><row><cell></cell><cell>(n=117)</cell><cell>muscle wasting %</cell><cell>muscle wasting %</cell><cell>value</cell></row><row><cell></cell><cell></cell><cell>(n=23)</cell><cell>(n=94)</cell><cell></cell></row><row><cell>Beta-blocker</cell><cell>79.2</cell><cell>88.9</cell><cell>77.9</cell><cell>0.68</cell></row><row><cell>ACE-inhibitors</cell><cell>63.6</cell><cell>54.0</cell><cell>63.3</cell><cell>&gt;0.99</cell></row><row><cell>Angiotensin receptor</cell><cell>29.9</cell><cell>33.3</cell><cell>29.4</cell><cell>&gt;0.99</cell></row><row><cell>blockers</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Digitals</cell><cell>13.0</cell><cell>11.1</cell><cell>13.2</cell><cell>&gt;0.99</cell></row><row><cell>Loop diuretics</cell><cell>48.05</cell><cell>33.3</cell><cell>50.0</cell><cell>0.84</cell></row><row><cell>Aspirin</cell><cell>54.5</cell><cell>66.6</cell><cell>52.9</cell><cell>0.5</cell></row><row><cell>Statins</cell><cell>68.8</cell><cell>77.8</cell><cell>67.6</cell><cell>0.71</cell></row><row><cell>Calcium channel</cell><cell>22.1</cell><cell>44.4</cell><cell>19.1</cell><cell>0.1</cell></row><row><cell>blocker</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Anticoagulants</cell><cell>29.9</cell><cell>11.1</cell><cell>32.4</cell><cell>0.27</cell></row></table></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Trends in prevalence and outcome of heart failure with preserved ejection fraction</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Owan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Hodge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Herges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Roger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Redfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="251" to="259" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Diagnosis of heart failure with preserved ejection fraction</title>
		<author>
			<persName><forename type="first">R</forename><surname>Wachter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Edelmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart Fail Clin</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="399" to="405" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Haykowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Brubaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kitzman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="265" to="274" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Borlaug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Melenovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Russell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="2138" to="2147" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Maeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Brunner-La Rocca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Kaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="855" to="863" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?</title>
		<author>
			<persName><forename type="first">P</forename><surname>Pellicori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kallvikbacka-Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Khaleva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiovasc Imaging</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="69" to="79" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kitzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Higginbotham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Cobb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Sheikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sullivan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1065" to="1072" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Near-maximal fractional oxygen extraction by active skeletal muscle in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Maskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jondeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cocke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Berkowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lejemtel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="2138" to="2142" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Impaired Aerobic Capacity and Physical Functional Performance in Older Heart Failure Patients with Preserved Ejection Fraction: Role of Lean Body Mass</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Haykowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Brubaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kritchevsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Eggebeen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kitzman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gerontol A Biol Sci Med Sci</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="968" to="975" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fülster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tacke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="512" to="519" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Edelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gelbrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Düngen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1780" to="1791" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">An overview of sarcopenia: facts and numbers on prevalence and clinical impact</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="129" to="133" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Epidemiology and consequences of sarcopenia</title>
		<author>
			<persName><forename type="first">Abellan</forename><surname>Van Kan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nutr Health Aging</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="708" to="712" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Functional and metabolic consequences of sarcopenia</title>
		<author>
			<persName><forename type="first">W</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nutr</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="998" to="1001" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Sarcopenia: origins and clinical relevance</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">H</forename><surname>Rosenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nutr</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="990" to="991" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Frailty and the aging male</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Haren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kevorkian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Banks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aging Male</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="135" to="140" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="253" to="259" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">on behalf of the Authors/Task Force Members and Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>in press</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Muscle wasting disease: a proposal for a new disease classification</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajs</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="187" to="194" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Paulus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tschöpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Sanderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2539" to="2550" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">A Recommendations for the evaluation of left ventricular diastolic function by echocardiography</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Nagueh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Appleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Gillebert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Echocardiogr</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="165" to="193" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Heymsfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aulet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="214" to="218" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Dual-energy X-ray absorptiometry body composition model: review of physical concepts</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pietrobelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Formica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Heymsfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page" from="941" to="951" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Abbatecola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Med Dir Assoc</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="403" to="409" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Appendicular skeletal muscle mass: effects of age, gender, and ethnicity</title>
		<author>
			<persName><forename type="first">D</forename><surname>Gallagher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Meersman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="229" to="239" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Epidemiology of sarcopenia among the elderly in New Mexico</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Baumgartner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gallagher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="755" to="763" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Exercise testing in adult normal subjects and cardiac patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bruce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Blackmon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Strait</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatrics</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="742" to="756" />
			<date type="published" when="1963">1963</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Physiologic responses of normal and pathologic subjects to a modified work capacity test</title>
		<author>
			<persName><forename type="first">J</forename><surname>Naughton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sevellus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Balke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Sports Med</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">201</biblScope>
			<date type="published" when="1963">1963</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">EQ-5D: a measure of health status from the EuroQol Group</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De Charro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Med</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="337" to="343" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">UK Population norms for EQ-SD. York Centre for Health Economics Discussion Paper</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hardman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Macran</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999-11">1999 Nov; 172</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A review of health utilities using the EQ-5D in studies of cardiovascular disease</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Matthew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kimberley</forename><forename type="middle">A</forename><surname>Dyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Linda</forename><forename type="middle">S</forename><surname>Goldsmith</surname></persName>
		</author>
		<author>
			<persName><surname>Sharples</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><surname>Buxton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Qual Life Outcomes</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Sarcopenia: etiology, clinical consequences, intervention, and assessment</title>
		<author>
			<persName><forename type="first">T</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Streeper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cawthon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Baldwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Taaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Osteoporos Int</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="543" to="559" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The wasting continuum in heart failure: from sarcopenia to cachexia</title>
		<author>
			<persName><forename type="first">Von</forename><surname>Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Nutr Soc</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maddocks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Kon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="213" to="218" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Target population for clinical trials on sarcopenia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cesari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pahor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nutr Health Aging</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="470" to="478" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Rolland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Czerwinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abellan</forename><surname>Van Kan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nutr Health Aging</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="433" to="450" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Inflammatory markers and loss of muscle mass (sarcopenia) and strength</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Schaap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Pluijm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Deeg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Visser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="526" to="e529" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS)</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1497" to="1499" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Are we closer to having drugs to treat muscle wasting disease?</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="83" to="87" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Piepoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Binno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Corrà</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="631" to="638" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The Muscle in Dire Straits: Mechanisms of Wasting in Heart Failure</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="2686" to="2688" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
